[1] CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures
Several factors can diminish or prevent the expected weight loss response to GLP-1 receptor agonists, even when medications are administered correctly
Ipamorelin: research protocols in the published literature have used subcutaneous doses in the low-microgram-per-kilogram range, typically delivered one to three times daily to capture multiple GH pulses across a 24-hour window
If weight loss is your primary goal, Wegovy is FDA-approved for that indication and has higher dose options
-Biotin promotes healthy, strong skin, hair and nails
Glucagon-like peptide-2 and the regulation of intestinal growth and function
